U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07545265) titled 'SKB565 for Injection in Advanced Solid Tumors' on April 16.
Brief Summary: This is a phase I/II clinical study to evaluate the safety and efficacy of SKB565 in participants with advanced solid tumors. The study includes a dose escalation stage, a dose expansion stage, and a indication expansion stage.
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Intervention:
DRUG: SKB565
IV infusion on Day 1 and Day 15 of each cycle, every 4 weeks (Q4W), until radiographic disease progression (PD), intolerable toxicity, participant request for discontinuation, lost to follow-up, or death (whicheve...